News

Increased Collaboration Promotes Improved Medical Diagnostic Capabilities and Health Outcomes
January 25, 2021 — The U.S. Department of Defense (DOD) has a long-standing history of developing medical countermeasures (MCMs) to combat deadly biological threats. Vaccines, diagnostics, and therapeutics serve in a fully-layered continuum of defense capabilities that both protect before exposure as well as to inform and treat after exposure. This set of... MORE

HHS, DOD purchase additional doses of Regeneron therapeutic to treat patients with mild to moderate COVID-19
January 12, 2021 — The Department of Health and Human Services (HHS) and the Department of Defense (DOD) today announced the purchase of 1.25 million additional treatment courses of Regeneron’s investigational monoclonal antibody therapeutic, a combination of casirivimab and imdevimab, to be delivered in the first half of 2021 to treat non-hospitalized, high-risk... MORE

DOD Awards University of Louisville $8.5 Million for COVID-19 Q-Griffithsin Repurposing Effort
December 9, 2020 — The JPM CBRN Medical leveraged an academic partnership to study the repurposing of a compound that shows promise against COVID-19... MORE

JPM CBRN Medical Tiger Team Takes Bold Action to Support Pandemic Response
December 4, 2020 — It is difficult to remember a time when “coronavirus” was not a part of our day-to-day vocabulary. The COVID-19 pandemic emerged from the shadows and threw the world into a tailspin, demanding ingenuity and resourcefulness as it pushed worldwide healthcare systems to their limits. As nations quickly scrambled to adapt and respond to the global... MORE

DOD-Funded Drug Remdesivir Receives FDA Approval for COVID-19 Treatment
December 1, 2020 — Yesterday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.’s Veklury® (Remdesivir) for treatment of hospitalized COVID-19 patients who are 12 years of age or older and weigh at least 40 kilograms (88 lbs). The approval of Veklury® was supported by the agency’s analysis of data from three randomized, controlled clinical... MORE

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
November 30, 2020 — SIOUX FALLS, S.D.--SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high-potency, fully human polyclonal antibodies without the need for human serum, today announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19... MORE

DOD Awards Partner Therapeutics $35 Million for Repurposing and Emergency Use of Leukine for COVID-19 Treatment
August 4, 2020 — The JPM CBRN Medical leveraged an industry partnership to accelerate the repurposing of an FDA-approved drug for COVID-19 treatment research... MORE

JBADS Lite: Decon at the Speed of Relevance
July 30, 2020 — On March 11, 2020, the World Health Organization declared a pandemic when the coronavirus wreaked havoc across the world. SARS CoV-2, the virus that causes COVID-19, is easily transmitted through respiratory droplets causing over nine million people to become infected and has taken the lives of 477,000 people, to date worldwide. Due to the ease of... MORE

Joint Biological Aircraft Decontamination System Lite

DOD Awards Johns Hopkins University $35 Million for COVID-19 Convalescent Plasma Research
July 30, 2020 — The JPEO-CBRND used existing contract capabilities to accelerate COVID-19 clinical trials... MORE

DOD Awards Industry Partner Immunome $13.3 Million for Biosynthetic Convalescent Plasma Development
July 28, 2020 — The JPM CBRN Medical leveraged an industry partnership to accelerate COVID-19 prevention and treatment research... MORE

News Search

News Archive - Search by Year and Month

May 2024 (1)
April 2024 (1)
March 2024 (3)
February 2024 (3)
January 2024 (2)
December 2023 (2)
November 2023 (2)
October 2023 (5)
September 2023 (6)
August 2023 (8)
July 2023 (2)
June 2023 (2)
May 2023 (3)
April 2023 (2)
March 2023 (1)
February 2023 (1)
January 2023 (1)
December 2022 (4)
November 2022 (1)
October 2022 (3)
September 2022 (5)
August 2022 (3)
July 2022 (3)
June 2022 (1)
May 2022 (1)
March 2022 (2)
February 2022 (2)
January 2022 (5)
December 2021 (1)
November 2021 (6)
October 2021 (2)
September 2021 (1)
July 2021 (1)
June 2021 (1)
May 2021 (8)
April 2021 (6)
March 2021 (2)
February 2021 (5)
January 2021 (4)
December 2020 (3)
November 2020 (1)
August 2020 (1)
July 2020 (3)
May 2020 (1)
April 2020 (1)
March 2020 (4)
February 2020 (1)
December 2019 (2)
November 2019 (2)
October 2019 (2)
September 2019 (2)
March 2019 (1)
January 2019 (2)
December 2018 (1)
October 2018 (1)
July 2018 (1)
April 2018 (1)
February 2018 (1)
December 2017 (1)
November 2017 (2)
September 2017 (1)
June 2017 (2)
January 2017 (3)
December 2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.